Abstract: Objective:To explore the effects of celecoxib on the proliferation and expression of epidermal growth factor receptor (EGFR ) inhibitor in lung cancer A 549 cells at different concentrations and different time points. Methods:A549 cells were cultured in RPMI- 1640and divided into five groups: normal control group; 12.5 μ mol/L celecoxib group; 25μ mol/L celecoxib group; 50μ mol/L celecoxib group; and 75 μ mol/L celecoxib group. The cells were treated with celecoxib in different doses ( 12 .5, 25 , 50 , and 75 μ mol/ L ) and for different periods ( 24 , 48 , and 72 hours ). Cell inhibition rate was detected by methyl thiazolyl tetrazolium ( MTT ). The apoptosis rate was measured using the Annexin V/PI and Hoechst 33258 staining method. The cell cycle was detected by flow cytometry, and the expression of EGFR mRNA was determined through real-time reverse transcriptase polymerase chain reaction. Results:Celecoxib induced a dose- and time-dependent growth inhibition in the intervention groups, as shown by MTT assay. Higher apoptosis rates ( P < 0.01 ) and G0/G1 stage cell ratios ( P < 0.01), and lower rates of S stage cell proportion ( P < 0.01), and EGFR mRNA expression ( P < 0.01) were observed in the celecoxib treatment groups compared with the normal control group. Conclusion: Celecoxib significantly inhibits the growth of A 549 cell, possibly by promoting apoptosis, G 0-G1 arrest, and downregulation of EGFR mRNA expression. Celecoxib has potential application in lung cancer treatment. Our study provides a new therapeutic use for celecoxib combined with EGFR inhibitors.